瘤抑制剂CYLD作为mTOR的二维基因酶,限制其活动
Stephanie A Fernandes1,2, Jiyoung Pan1,2, Diana S Terziyska1
1Max Planck Institute for Biology of Ageing (MPI-AGE), 50931 Cologne, Germany.
bioRxiv : the preprint server for biology
|September 15, 2025
概括
瘤抑制剂CYLD二维基因酶 (DUB) 通过去除泛基因链,直接调节mTORC1/2的活动. CYLD的失活导致mTOR过活化,影响细胞生长和存活,并与CYLD皮肤综合征有关.
科学领域:
- 细胞信号通道是细胞信号通道.
- 分子生物学分子生物学
- 用乌比奎丁修饰的蛋白质.
背景情况:
- 机械/哺乳动物目标的拉巴胺素 (mTOR) 信号传递对于细胞功能,健康和疾病至关重要.
- 对于mTOR在调节其活动中的作用尚不清楚.
- CYLD是一种已知的瘤抑制剂,但其在mTOR信号传递中的直接点和功能尚不清楚.
研究的目的:
- 通过不偏见的查,识别mTOR信号传递的新型调节剂.
- 阐明CYLD在控制mTOR活动和无处不在中的作用.
- 研究CYLD,mTOR过活化和CYLD皮肤综合征 (CCS) 之间的联系.
主要方法:
- 无偏的RNA干扰 (RNAi) 屏幕用于识别mTOR调节器.
- 生物化学试验用于研究蛋白质相互作用和二维基因酶活性.
- 细胞测试评估mTORC1/2活动,蛋白质合成和细胞死亡.
- 对C. elegans模型和人类患者活检的分析.
主要成果:
- 鉴定出CYLD二维基因酶 (DUB) 是mTORC1和mTORC2.2的直接负调节剂.
- CYLD从mTOR中去除了与K63结合的乌比奎链,控制了它的活动.
- CYLD功能的丧失导致mTORC1/2过度激活,增加蛋白质合成,细胞生长和抵抗细胞死亡.
- 沉默*C. elegans*正义 *cyld-1* 扭转了低TORC1突变的寿命延长.
- 在CCS患者的皮肤活检中,CYLD无活化与mTORC1过活化相关.
结论:
- 通过对mTOR无处不在的直接控制,CYLD充当了mTOR过度激活的关键哨兵.
- 由于CYLD无活化导致的失调的mTOR活性可能会导致CCS瘤的发病.
- 针对CYLD-mTOR轴可以为CCS和相关疾病提供治疗策略.
相关概念视频
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
PI3K/mTOR/AKT Signaling Pathway
5.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.4K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Anaphase Promoting Complex
3.3K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.3K
M-Cdk Drives Transition Into Mitosis
6.3K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.3K


